BMEA

Biomea Fusion, Inc. [BMEA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BMEA Stock Summary

Top 10 Correlated ETFs

BMEA

Top 10 Correlated Stocks

BMEA

In the News

BMEA Financial details

Company Rating
-
Market Cap
459.51M
Income
-105.49M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
86
Optionable
No
Shortable
Yes
Earnings
07 Aug 2023
P/E
-5.29
Forward P/E
-
PEG
-0.59
P/S
-
P/B
5.83
P/C
-
P/FCF
-7.22
Quick Ratio
4.62
Current Ratio
4.74
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.27
EPS next Y
-
EPS next Q
-
EPS this Y
57.8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.29%
-
-
-
-
SMA20
-14.73%
SMA50
-46.18%
SMA100
-58.97%
Inst Own
-
Inst Trans
-
ROA
-81%
ROE
-77%
ROC
-1.04%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.125-43.69
52W High
-91.95%
52W Low
-56.75%
RSI
34.92
Rel Volume
0.29
Avg Volume
1.02M
Volume
294.03K
Perf Week
-0.86%
Perf Month
-13.72%
Perf Quarter
-54.11%
Perf Half Y
-44.82%
-
-
-
-
Beta
-1.05502
-
-
Volatility
0.09%, 0.3%
Prev Close
-5.21%
Price
3.46
Change
-3.62%

Something similar

Top by Market Cap
TL0.DE
0YXG.L
FXAIX
TSLA
VTSAX
Top Correlated ETFs
ITB
IDX
NAIL
FTXR
MDCP
Top Correlated Stocks
AEO
PYXS
LNTH
ATHA
AKYA
Similar Market Cap
0685.HK
PANR.L
CALSOFT.NS
0531.HK
SYBY.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 1.02M
  • Market Capitalization 459.51M
  • Employee 86
  • CEO Mr. Thomas Andrew Butler
  • Headquarters Redwood City,CA,US
  • IPO Date 2021-04-16
  • Website https://biomeafusion.com

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.